Sickle cell disease occurs in about 1 out of every 365 Black or African American births in the United States, according to host Bapu Jena.
“In fact, sickle cell disease occurs in around 1 out of every 365 Black or African American births.”

17 Feb 2023 · 29m · Bapu Jena, Andrew Lowe, Jimmy Olaher · 24 quoted facts
Gene cures for rare diseases will cost millions of dollars each, and the way American health care pays for drugs cannot handle that. Economist Andrew Lowe argues the fix is a subscription model. A payer would pay a small monthly fee per member, and the drugmaker would treat every patient who needs the drug. This would spread risk widely and give investors steady income.
The episode sets one patient's cure against the money problem. Jimmy Olaher's CRISPR treatment ended his sickle cell pain, and the therapy is now up for FDA approval. Lowe says the real obstacles are cultural and legislative, not economic. Because sickle cell mostly affects Black patients and is common in Africa, the host stresses that affordability is an ethical and global question too.
Lowe says a hemophilia patient's lifetime care can cost more than the one-time price, and federal policy values a statistical life at about $10 million. Against those numbers, the price looks cheap, even though the lump sum is hard to pay.
A self-insured company with 1,000 employees has about a $6 million annual budget, so a single $3.5 million treatment would take over half of it. That concentrated risk is why one-time cures are hard to cover.
Lowe cites a Goldman Sachs analysis finding drugmakers have more financial incentive to sell ongoing treatments than one-time cures. A cure empties a company's customer base, while a daily pill keeps revenue coming.
Louisiana paid Gilead a set amount per member per month and in return got as much hepatitis C drug as it needed. Lowe proposes extending this to rare diseases, which would turn lumpy sales into a steady stream and pool risk across many people.
Today payers lose money by screening for rare diseases, because finding patients creates expensive bills. Under subscriptions, plans want every patient found, so Lowe says diagnosis would speed up.
Rare diseases have few patients, so the price has to recover development costs from a small market. Andrew Lowe also notes that a patent gives only about 10 years of exclusive sales after a long approval process, and that the price reflects the lifetime of costly care the cure replaces.
Instead of paying millions per patient, a state or employer pays the drugmaker a small monthly fee for each member covered. In return, the drugmaker treats everyone who develops the disease, and Lowe points to Louisiana's deal with Gilead for hepatitis C as the precedent.
Lowe says a drug mortgage fails because patients change insurers. The first plan would be stuck making payments for someone who is no longer a customer, which is why he favors subscriptions.
After a CRISPR gene-editing trial in Nashville, with an infusion in September 2021, his constant pain went away within about two weeks. He says he used to barely sleep because of pain and now wakes up energetic.
Lowe says the main barriers are cultural: many health plans are not set up for subscriptions, and some state laws must change to let Medicaid take part. The host adds open questions about who sets the fee and what happens to the roughly 30 million Americans without insurance.
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Sickle cell disease occurs in about 1 out of every 365 Black or African American births in the United States, according to host Bapu Jena.
“In fact, sickle cell disease occurs in around 1 out of every 365 Black or African American births.”
Nigeria has one of the world's largest sickle cell disease populations, at around 4 to 6 million people, according to the host.
“But he's originally from Nigeria, which has one of the largest sickle cell disease populations in the world. at around 4 to 6 million people.”
Sickle cell disease is caused by a single mutation in a single gene, which makes red blood cells rigid and sickle-shaped.
“It's caused by a single mutation in a single gene. People with sickle cell disease produce red blood cells that are rigid and sickle-shaped.”
In January 2020 Jimmy Olaher, his wife and their newborn moved part-time to Nashville, where his CRISPR sickle cell trial took place.
“In January 2020, Jimmy, his wife, and their newborn moved part-time to Nashville, where the trial was taking place”
Jimmy Olaher received his CRISPR infusion in September 2021, about 18 months after starting the preparation process.
“Finally, 18 months later, in September 2021, it was time.”
CRISPR consists of two molecules: an enzyme that acts as DNA scissors and a piece of genetic material that tells the enzyme where to cut.
“it consists of just two molecules, an enzyme that acts as a pair of DNA scissors, and a special piece of genetic material that tells the enzyme where in the DNA to cut.”
Gene therapies that existed before CRISPR relied on modified viruses to deliver new genetic material into a patient's cells.
“There were gene therapies before CRISPR, but they relied on modified viruses to deliver new genetic material into a patient's cells.”
The CRISPR treatment that cured Jimmy Olaher's sickle cell disease is the first CRISPR-based therapeutic up for approval by the U.S. FDA.
“The treatment that cured Jimmy's sickle cell disease is now the first CRISPR-based therapeutic up for approval by the FDA, meaning it could hit the market as early as this year.”
A hemophilia gene therapy cure became the world's most expensive drug when it launched at $3.5 million per treatment.
“Last year, a gene therapy cure for the blood clotting disorder hemophilia broke the record for the most expensive drug in the world when it hit the market at $3.5 million per treatment.”
According to Andrew Lowe, the U.S. government uses a value of a statistical life, most recently about $10 million, in policy decisions.
“In fact, the United States government, when they make policy decisions, they use a concept called the value of a statistical life. The most recent estimate is about $10 million.”
According to Andrew Lowe, a U.S. patent on a new drug gives 20 years of exclusivity.
“You come up with a new drug, you get 20 years of exclusivity where you are the only person that can make use of that idea.”
Andrew Lowe says FDA approval of a new drug generally takes about 5 to 15 years, depending on the disease.
“the FDA approval process generally takes on the order of 5 to 15 years, depending on the nature of the disease.”
Andrew Lowe says a self-insured employer with about 1,000 plan members has an annual medical budget of about $6 million.
“With a thousand members of your plan, your annual budget is about $6 million.”
Andrew Lowe says Goldman Sachs analyzed one-time cures and concluded drug companies have an incentive to develop chronic treatments rather than cures.
“In fact, a few years ago, Goldman Sachs looked at the economics of these one-time cures.”
Andrew Lowe published a paper in 2016 proposing a mortgage-like payment model to finance expensive cures.
“Economist Andrew Lowe published a paper in 2016 proposing we use a similar payment model to finance expensive cures for chronic diseases.”
Andrew Lowe co-founded a company that would act as a payment platform for a drug subscription model.
“I should note that Andrew Lowe co-founded a company that would act as a payment platform for such a subscription model.”
Gilead's hepatitis C drug Sovaldi was approved by the FDA and came to market in December 2013.
“The medication was approved by the FDA and came to market in December 2013.”
Gilead's originally proposed price for Sovaldi was $84,000, which Andrew Lowe calls a bargain from an economist's point of view.
“Gilead's original proposed market price was $84 ,000. And from an economist's point of view, that was a bargain.”
Louisiana agreed to pay Gilead a fixed monthly amount per member, and Gilead agreed to treat all people in the state who needed the hepatitis C drug.
“the state of Louisiana developed an interesting approach. They agreed to pay Gilead a certain amount of money per member per month”
The three most expensive drugs in the world are all treatments for rare genetic diseases approved within the past few years, according to the host.
“Today, the three most expensive drugs in the world are all treatments for rare genetic diseases, all approved within the past few years.”
Over 200 million statin prescriptions are filled in the United States each year, according to the host.
“Over 200 million statin prescriptions are filled in the U.S. each year.”
Scientists who developed statins in the mid-1980s were aiming to treat the genetic disease familial hypercholesterolemia.
“The scientists who developed statins in the mid-1980s were hoping to cure a genetic disease called familial hypercholesterolemia”
The host says nearly 30 million Americans have no health insurance and would be left out of the subscription model.
“And what about the nearly 30 million Americans who don't have any health insurance?”
Bapu Jena and a colleague named Athena later used the 1987 NFL Players Association strike as a natural experiment to study whether playing pro football affects health.
“In 1987, the NFL Players Association held a strike. 30 years later, my friend Athena and I did a study that used that strike as a natural experiment”
Jimmy describes years of pain and sleeplessness, which shows how much a cure would change a patient's life.
“It's like a succession of time bombs because first your spleen goes”
The host describes Jimmy's trial treatment and explains CRISPR as a tool for editing a patient's own genes.
“a small syringe of DNA that took about 30 seconds to infuse”
The host frames the question of who can afford a cure priced like the $3.5 million hemophilia drug.
“will anyone be able to afford it?”
Andrew Lowe says finance can drive which science gets pursued, and that bundling rare diseases into one portfolio makes them more attractive to investors.
“finance actually plays a huge role in drug development, sometimes too big a role”
Lowe compares the price with the lifetime cost of care and with the government's value of a statistical life.
“it turns out that $3.5 million is actually a pretty good deal”
Lowe shows how a single cure could consume more than half of a small employer's health budget, and why insurers have little reason to favor cures.
“you're going to have to write a $3.5 million check”
The episode explains how a per-member monthly fee worked for Sovaldi and could cover rare diseases.
“They agreed to pay Gilead a certain amount of money per member per month”
Lowe says the obstacles are cultural and legislative, and the host argues rare disease cures could pave the way for treating common diseases, as statins did.
“Many health plans are not set up to be part of subscription models.”
Jimmy describes survivor's guilt and the need to bring the treatment to Africa, where sickle cell is far more common.
“What comes next in an ideal world would be the globalization of this technology.”
Believe in holiday magic? Then follow the twinkling lights to holidays in Yauntville, Napa Valley's most festive town. Discover more than 50 merry experiences, from holiday craft classes and wine tastings, to cooking demonstrations and charming store open houses. Add sparkling holiday lights, luxurious resorts, and incredible cuisine, and you found your own holiday wonderland. Make this season extraordinary in Yauntville, from Thanksgiving weekend through New Year's. Visit yauntville.com and make your own holiday magic.
Your business relies on technology every day, but how confident are you in the security behind it? As your business evolves, so do the cybersecurity challenges that come with it. That's why BPM's Cybersecurity Risk Assessments help leaders better understand cyber risk, identify vulnerabilities, and develop a practical roadmap for stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com slash cyber.
Jimmy, nice to meet you virtually. Thank you for doing this. I know it's early in the morning.
Thank you for having me. I am an early riser. What time do you get up normally? 4 a.m. Did you always wake up at 4 a.m.? No, actually, for most of my life, I barely slept because I had this thing called pain somnia that I think me and my wife coined. When you have so much pain that you can't sleep. Why did you have so much pain? I had a disease called sickle cell anemia.
It's like a succession of time bombs because first your spleen goes, then your gallbladder, then your hips, and all your organs are in jeopardy. And aside from that, there's the cornerstone of pain that you have to live with nonstop. Lots and lots of pain.
Jimmy Olaher lives in Atlanta, where he works in e-commerce. But he's originally from Nigeria, which has one of the largest sickle cell disease populations in the world. at around 4 to 6 million people. In the United States, around 100 ,000 people have sickle cell disease, so we classify it as a rare disease. Most Americans with the disease have African ancestry. In fact, sickle cell disease occurs in around 1 out of every 365 Black or African American births.
It's caused by a single mutation in a single gene. People with sickle cell disease produce red blood cells that are rigid and sickle-shaped. As a result, they can't carry oxygen and also clog small blood vessels, causing extreme pain episodes known as crises, like the ones Jimmy described.
Growing up in Nigeria at the time, they had no breakthrough pain medication. When I'll have my crisis, it'll be a menthol rub and some Advil.
Jimmy's family moved to the U.S. when he was a child so he could get better care. But nothing made much of a difference. He considered a bone marrow transplant, but neither of his sisters were good donor matches. Jimmy's pain crises got worse as he got older. The disease dominated his life and, eventually, his wife's.
Everything we did, we had this child called sickle cell that we had to do it with. I almost died on my honeymoon because of the sickle cell.
You told me that you used to spend a lot of time in bed with pain somnia. You told me that you now wake up at 4 o 'clock in the morning energetic and ready to do something with your day. How did this all come about? This came about by something called CRISPR. In the fall of 2019, Jimmy got a news alert that changed everything. It was about a clinical trial for a novel cure that uses CRISPR gene editing technology to fix the genetic mutation that causes sickle cell disease.
Jimmy reached out to the doctors running the trial, and they called him back the next day to start the qualification process. This all coincided with another life-altering event for Jimmy.
My wife has a son December 5th, 2019, and I think it was a few days before Christmas. December 20-something, they called me and officially told me that I qualified. How'd you feel? I was really just desperate, knowing that I was going to be a father on just how much sickle cell can be a demanding companion.
In January 2020, Jimmy, his wife, and their newborn moved part-time to Nashville, where the trial was taking place and started the lengthy DNA collection and transplant preparation process. This was no walk in the park. He endured blood draws that lasted up to eight hours and weeks of chemotherapy. Finally, 18 months later, in September 2021, it was time.
After going through that long, painstaking process, It all amounted to a small syringe of DNA that took about 30 seconds to infuse. And my life changed completely. I remember probably two weeks after I had been infused, I started to notice like, wow, I actually don't need any pain medication today because I don't feel pain like I used to. That pain that just lingers all the time, all of a sudden was gone.
Jimmy no longer lives with sickle cell disease, a fate that had seemed impossible. Ironically, the cutting-edge treatment that made it possible relies on something that bacteria evolved billions of years ago, called CRISPR. As I explained last week, it consists of just two molecules, an enzyme that acts as a pair of DNA scissors, and a special piece of genetic material that tells the enzyme where in the DNA to cut. Bacteria use CRISPR to destroy invading parasites.
In humans, that same mechanism can be used to cut out defective genes and even repair them. There were gene therapies before CRISPR, but they relied on modified viruses to deliver new genetic material into a patient's cells. CRISPR is revolutionary because it allows us to edit a patient's genes directly. The treatment that cured Jimmy's sickle cell disease is now the first CRISPR-based therapeutic up for approval by the FDA, meaning it could hit the market as early as this year.
And what it does, one thing is nearly certain, it will be very expensive. Last year, a gene therapy cure for the blood clotting disorder hemophilia broke the record for the most expensive drug in the world when it hit the market at $3.5 million per treatment. If the CRISPR cure for sickle cell disease or any other genetic condition comes with a price tag like that, will anyone be able to afford it? From the Freakonomics Radio Network, this is Freakonomics MD.
I'm Bapu Jena. Last week on the show, we laid out the pieces of this economic puzzle. Today, we'll meet an economist who thinks he solved it.
With the right kind of financing, it actually ends up accelerating our ability to treat these patients.
And we'll look at how solving this problem could have ripple effects across health care. Thank you, rare disease community, for showing us the path for how to address a much bigger killer.
Over a seven-year period, six people that were close to me, including my mother, all died of cancer.
That's Andrew Lowe. He's a professor of finance at the MIT Sloan School of Management.
The more I read about what my friends and family were going through, the more surprised I was to learn that finance actually plays a huge role in drug development, sometimes too big a role, driving the source of scientific discovery rather than the other way around.
There are diseases that have large markets, diabetes, high blood pressure, where you can expect as an innovator, if you develop an important treatment, that there's a large number of people who will be able to take the drug. But for rare diseases that have a genetic basis, the market size is very small. And so the ability of an investor who's thinking about developing a treatment for that disease is going to be limited by the fact that there's only a certain number of people that they can sell that drug to.
How does that play out when it comes to financial engineering?
Very often, when you're focusing on just one disease, by itself, it may not be economical to develop the particular therapeutic. But if you combine multiple diseases into a single financial portfolio, all of a sudden the risk-reward trade-off becomes more attractive. If you can put together a large number of projects that are statistically independent, that their success and failure have no bearing on the other successes and failures, that's the best way of reducing risk in a portfolio.
How do I think about risk spreading across diseases versus the fact that a rare disease, if it's successful, will only have a few people who can use it?
Well, the question that you have to answer is, what is it worth to those patients and to our healthcare system to be able to treat them? For example, certain ultra-rare diseases may seem really expensive to treat. But remember that those patients are going to have to be addressed by the healthcare system one way or another. They're going to need medical care, and in some cases, the medical care may be even more expensive than the cure.
The most expensive drug in the world right now is a one-time cure for a rare disease called hemophilia. And that drug costs something like $3.5 million. And so under this framework, help me understand why it's so expensive.
Hemophilia is a very difficult disease to deal with without the cure. The lifespan of a hemophiliac patient is fraught with episodes where they are going to start bleeding and they need to have treatment, and those treatments often can lead to infections. One particular episode could cost the healthcare system upwards of several $100,000. So if you think about a lifetime, it turns out that $3.5 million is actually a pretty good deal.
In fact, the United States government, when they make policy decisions, they use a concept called the value of a statistical life. The most recent estimate is about $10 million. So $3.5 million is in fact a bargain because the value of that life lost
could be on the order of $10 million. In most markets, prices are determined by the supply and not the demand. For example, if it's a really hot day and you just finished running six miles, You might go to the CVS pharmacy and buy a bottle of water. You might be willing to spend $10 for it, $20 for it, because you're really thirsty. But you can buy it for $1.50 because if CVS tried to charge you $3, Walgreens right across the street would charge you $2.
And then the gas station right across the street would charge you $1.50. Through competition, based on the cost of producing and distributing that water bottle, we get down to $1.50. We generally think of that as being good for society. What you're describing is price being more reflective of the underlying value, which in many markets we view as a bad thing. The challenge here in innovative markets is you want to make sure that innovation enters the market in the first place.
There's an added element here that I think is worth considering, and that's the U.S. patent system. You come up with a new drug, you get 20 years of exclusivity where you are the only person that can make use of that idea. In the case of drug development, we have to test the drug first, and the FDA approval process generally takes on the order of 5 to 15 years, depending on the nature of the disease. So let's call it 10 years.
During that time, you're earning no money. You're charging nothing. But then, if you get the drug approved, you'll have something on average of about 10 years left of that 20-year patent. After those 20 years are up, the idea is available to everybody under the sun, and now the price can drop dramatically. The pricing of novel cures is one issue,
but there's another problem, one that stems from how we pay for medical care in this country.
If you're a company that's got about a thousand employees, most likely you are self-insured. That means you're using your own money to pay for your particular employee's medical needs in any given year. With a thousand members of your plan, your annual budget is about $6 million. If one of them ends up developing a case of hemophilia, you're going to have to write a $3.5 million check. That's more than 50 % of your entire annual budget going to one patient.
And that's a problem.
It does strike me that absent a solution to the problem, the company doesn't have an incentive to give you a one-shot cure. In fact, they have an incentive to provide you a pill that you have to remember to take every day, and that's inconvenient for the rest of your life.
I couldn't agree with you more. In fact, a few years ago, Goldman Sachs looked at the economics of these one-time cures. They looked at the economics of these chronic treatments, and they came to the conclusion that there is a significant incentive for drug companies to develop chronic treatments as opposed to cures.
So how can we make one-time cures affordable for patients and attractive to investors? We need to have that conversation sooner rather than later. That's after the break. I'm Bapu Jena, and this is Freakonomics MD.
Hey guys, I had to send you this voice message to tell you about my amazing first visit to Kaiser Permanente. You know, in the time it takes me to finish recording this message, I'll have walked from my doctor's office to the pharmacy. They do it a little different here. So like in the same building, you've got your doctor's office, the lab where they do your tests, and the pharmacy. I'm here. That was quick, right? Everything you need for your health, all in one place.
Kaiser Permanente, a better idea for healthcare. Believe in holiday magic? Then follow the twinkling lights to holidays in Yontville, Napa Valley's most festive town. Discover more than 50 merry experiences, from holiday craft classes and wine tastings, to cooking demonstrations and charming store open houses. Add sparkling holiday lights, luxurious resorts, and incredible cuisine, and you found your own holiday wonderland. Make this season extraordinary in Yauntville from Thanksgiving weekend through New Year's. Visit yauntville.com and make your own holiday magic.
Your business relies on technology every day, but how confident are you in the security behind it? As your business evolves, so do the cybersecurity challenges that come with it. That's why BPM's Cybersecurity Risk Assessments help leaders better understand cyber risk, identify vulnerabilities, and develop a practical roadmap for stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com slash cyber. When you decide to buy a home, you're getting a lifetime worth of housing. And to pay for a lifetime worth of housing up front in cash is difficult.
So we figured out that you can get a mortgage. A 30-year mortgage spreads out the payment of your value of housing over a lifetime of 30 years.
Economist Andrew Lowe published a paper in 2016 proposing we use a similar payment model to finance expensive cures for chronic diseases.
What you're getting for that one-time payment is a lifetime of health. So why not create a kind of a drug mortgage that will allow us to spread the payments over a number of years?
It turns out there's one big reason why not. Remember that in most cases, the payer isn't the patient, but an insurance provider acting on their behalf. And in the U.S., we have a mix of public insurance programs, private insurance companies, and independent employer-funded insurance plans that make up our multi-payer system.
The problem with these drug mortgages is that if you leave that health plan to go to another one, then you left the first health plan with that series of mortgage payments, but you're not paying that health plan premiums as a healthy individual. So there has to be a better way to be able to make these more affordable. And that's the current proposal that I've been working on, which is using a subscription model.
Before we get into it, I should note that Andrew Lowe co-founded a company that would act as a payment platform for such a subscription model. But he wasn't the first person to come up with this idea.
There is a precedent. If you look back a few years to the rollout of Solvaldi, the drug that cures hepatitis C.
Hepatitis C is not a rare disease. In the U.S. alone, as many as 4.7 million people live with hep C. It's a viral infection that spreads through the blood and causes liver damage. It had always been hard to treat until a drug company called Gilead developed Sovaldi. The medication was approved by the FDA and came to market in December 2013.
Gilead's original proposed market price was $84 ,000. And from an economist's point of view, that was a bargain. But the problem is, given the number of people that have hepatitis C at the time, if every one of them had to pay $84 ,000, that would have easily blown the budgets of state Medicaid plans and many independent insurers that had to pay for these costs. And so the state of Louisiana developed an interesting approach. They agreed to pay Gilead a certain amount of money per member per month And in exchange for that subscription fee, Gilead agreed to treat anybody and everybody in the state of Louisiana that needed the drug.
It provides drug companies with cash flows immediately based upon the number of members and the per member per month fee. And it provides the state of Louisiana with as much drug as they'll ever need. And I think that that would apply very directly to rare diseases. Imagine that you've got a company with a thousand employees, they're self-insured, and they are worried about getting hit with one of these rare diseases that can wipe out their budget.
They can go to the drug manufacturer now and say, let's enter into an agreement where we will pay you 50 cents per member per month. You agree that if we develop any of the rare diseases that your company covers, you will treat our employees for free. It's not really for free
because the payer, in this case the employer, is paying the small monthly premium. This payment plan operates sort of like insurance, but instead of being provided directly to an individual by a traditional insurer, it's provided to the traditional insurers by the drug companies themselves. For the drug makers, it offers the prospect of predictable recurring payments rather than big sporadic purchases. That change is especially popular with investors. As soon as
they get their drug approved and are ready to deploy that drug, they will start getting payments per member per month. So it turns a very lumpy cash flow into a relatively smooth and steady stream. and that is a lot less risky and from Wall Street's perspective a lot more attractive.
It also solves a problem for insurance providers. Today, the three most expensive drugs in the world are all treatments for rare genetic diseases, all approved within the past few years. And we know that more multi-million dollar drugs, like the CRISPR cure for sickle cell disease, are on the horizon. Those costs are a challenge for payers, from private insurance companies to Medicaid to employers with independent plans. But providing those drugs on a subscription basis would effectively create a single-payer system for that particular drug.
With a single-payer system, everybody is part of that risk pool. You've reduced the level of risk across as many people as you possibly can. From a purely economic efficiency point of view, that is the best outcome. We have a very, very complex multi-payer system, but we do have the chance right now to focus on a single-payer system for rare diseases.
One of the big problems for these types of diseases is that they go under or undiagnosed for many years. Do you think that having A, the technology to be able to treat more of these diseases and B, a financial model to be able to pay for these treatments might also create an incentive to diagnose these diseases earlier?
Without a doubt. I've spoken to a number of pancreatic oncologists who've told me that they feel more like morticians than oncologists or doctors. They're not healers because they have very little in their toolkit to heal. If we can provide doctors with therapies that will save patient lives, they will absolutely go out there and try to diagnose every single instance of this disease because their goal is to save as many lives as possible. With the subscription model, The health plans that are paying these premiums are going to want to make sure that they get their money's worth by identifying every single patient that's out there.
This brings us back to the conversation I had last week with the physician and computer scientist, Gaurav Singhal. He talked about the role artificial intelligence could play in diagnosing rare genetic diseases at scale. But his vision had an economic hurdle. The payer is caught in a bind here, because if we screen more for rare conditions, we identify more patients who will need to have expensive treatments. If drug companies entered into subscription agreements with payers, their incentives would realign, as Andrew described.
That's one of the reasons I'm so excited about this financing. Without it, financing ends up being a tremendous roadblock. But with the right kind of financing, it actually ends up accelerating our ability to treat these patients.
So what are the barriers? What are the challenges to implementing this sort of subscription model?
Really, the challenges are cultural. Many health plans are not set up to be part of subscription models. So we're going to need to see changes in certain state legislation to allow state Medicaid plans to engage in these kinds of contracts. Certainly, the state of Louisiana was a pioneer, but other states have followed suit. And so I suspect that it's just really a matter of time.
There are some challenges this proposal has to overcome. For one thing, who determines the subscription fee? And what about the nearly 30 million Americans who don't have any health insurance? They're left out of this picture entirely. These issues don't mean that the subscription model won't work. The problems it aims to solve are just really complicated. One solution isn't going to fix everything. But innovative ideas like this one get us closer.
What I think will drive all of these innovations is need. Once we start getting gene therapies for more common treatments, then we'll have no choice but to think more seriously about these payment models because the healthcare system cannot deal with a broad gene therapy for a large indication like macular degeneration or heart disease. But those gene therapies are on their way.
Dr. Fyodor Ernov, the geneticist I spoke with last week, also sees CRISPR having a much broader impact on the horizon. Many of the medical advances that we have today that are widespread did not start as big endeavors to make a huge impact. Statins are a great example. Over 200 million statin prescriptions are filled in the U.S. each year. They're used to lower cholesterol and reduce the risk of heart disease and stroke. But they didn't start out that way.
The scientists who developed statins in the mid-1980s were hoping to cure a genetic disease called familial hypercholesterolemia, where people have persistently high cholesterol levels. It's not a rare disease, but the most serious form of it is. And the pharma companies that were building these statins said, aha, this works in genetic heart disease. Could it work in common heart disease? And guess what it did? And then they said, wow, this is doing such good to the patients that I'm wondering if we can just give it as a preventative measure.
And that's what happened. So as more and more examples of CRISPR's safe and effective use for these rare diseases come to light, then I'm really hopeful that pharma will realize that CRISPR potentially could be deployed in diseases that are a lot more prevalent. and say, thank you, rare disease community, for showing us the path for how to address a much bigger killer.
Why the price of a drug is so high that certain patients are going to die because they can't afford it, those are not economic questions. Those are ethical questions.
That's economist Andrew Lowe again.
We need to have a national, all-stakeholder conversation about these various life-saving therapeutics and how we're going to be able to afford them. We need to have that conversation sooner rather than later.
In the case of sickle cell disease, we need to have that conversation now. As I mentioned at the top of the episode, the CRISPR-based treatment that cured Jimmy Olaher is now up for FDA approval. And the ethical questions around its affordability are compounded by the fact that sickle cell disease affects mostly Black and African American people who experience higher rates of poverty in the U.S. and have a long history of being mistreated or overlooked by our medical system.
If our drug financing landscape doesn't change, the cure will remain out of reach for many patients who need it.
It weighs significantly on me this survivor's guilt that you feel because I've obviously talked to a lot of people that have sickle cell and even have friends that have sickle cell that will never get to experience this. And in a way, that kind of detaches you from them. You know, a lot of people reach out to me, particularly in the sub-Saharan parts of Africa, where only God knows how soon this is going to get there, messaging me about how they can get access to something like it's not just for themselves, but to even save their children.
Sickle cell disease is also a good reminder that this economic puzzle is not an American issue. It's a global issue.
What comes next in an ideal world would be the globalization of this technology. If every American, the 100 ,000 plus that suffer from the disease get cured, we haven't even touched a fraction of the population that suffers from this disease. I know it's going to be difficult. Obviously, it's no small feat, but I feel like there are a lot of smart people working on it.
Imagine a future where organizations and governments across the globe collaborate to eradicate sickle cell disease everywhere, like they pledged to do with polio 33 years after an American scientist developed the first successful vaccine. Imagine a future where the world comes together to eradicate all genetic diseases. That future is still a fantasy. But as far as technology goes, the pieces to make that possible are coming together, and maybe even some of the economic pieces too. Do you think we'll get there in our lifetimes?
Ever? I don't know, but we have to try. That's it for today. I'd like to thank my guests this week, Jimmy Olaher, Andrew Lowe, Gaurav Singhal, and Fyodor Ernov. And thanks to you, of course, for listening. Let me know what you thought about this two-part episode. I'm at bapu at freakonomics.com. That's B-A -P-U at Freakonomics.com. We'll be off next week, but back in two weeks with an all-new episode. The replacement player situation gave us this really interesting natural experiment where you had people that wouldn't have been in the NFL otherwise play a couple games.
In 1987, the NFL Players Association held a strike. 30 years later, my friend Athena and I did a study that used that strike as a natural experiment to try to figure out, is playing professional football good or bad for your health? That survival advantage is not actually something that materializes when you have a more fair comparison. We'll talk about our findings and also some other unconventional ways you could try to answer this question. That's coming up in two weeks on the next episode of Freakonomics MD.
Freakonomics MD is part of the Freakonomics Radio Network, which also includes Freakonomics Radio, No Stupid Questions, and People I Mostly Admire. All our shows are produced by Stitcher and Renbud Radio. You can find us on Twitter, at DrBapuPod. This episode was produced by Julie Canfer and Lyric Baudich. It was mixed by Eleanor Osborne. Our executive team is Neil Carruth, Gabriel Roth, and Stephen Dubner. Original music composed by Luis Guerra. If you like this show or any other show in the Freakonomics Radio Network, please recommend it to your family and friends.
That's the best way to support the podcasts you love. As always, thanks for listening.
I wish I'd written down what you just said. You know, it's going to be on the podcast, so you don't have to worry about it. We'll have a transcript.
The Freakonomics Radio Network. The hidden side of everything. Stitcher. Believe in holiday magic? Then follow the twinkling lights to holidays in Yontville, Napa Valley's most festive town. Discover more than 50 merry experiences from holiday craft classes and wine tastings to cooking demonstrations and charming store open houses. Add sparkling holiday lights, luxurious resorts, and incredible cuisine, and you found your own holiday wonderland. Make this season extraordinary in Yauntville from Thanksgiving weekend through New Year's. Visit yauntville.com and make your own holiday magic.
Your business relies on technology every day, but how confident are you in the security behind it? As your business evolves, so do the cybersecurity challenges that come with it. That's why BPM's Cybersecurity Risk Assessments help leaders better understand cyber risk, identify vulnerabilities, and develop a practical roadmap for stronger security. Build confidence in your cybersecurity strategy. Learn more at bpm.com slash cyber.